Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lirilumab + Azacitidine in Refractory/Relapsed AML
NCT02399917Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2015
- Primary completion
- Jul 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of lirilumab in acute myeloid leukemia (AML) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Overall Response Rate at 3 months. Started Apr 2015; status: terminated.
02
Drugs
lirilumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02399917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02399917.